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Abstract Olfactory ensheathing cell (OEC) transplanta-
tion emerged some years ago as a promising therapeutic
strategy to repair injured spinal cord. However, inhibitory
molecules are present for long periods of time in lesioned
spinal cord, inhibiting both OEC migration and axonal
regrowth. Two families of these molecules, chondroitin
sulphate proteoglycans (CSPG) and myelin-derived in-
hibitors (MAIs), are able to trigger inhibitory responses in
lesioned axons. Mounting evidence suggests that OEC
migration is inhibited by myelin. Here we demonstrate that
OEC migration is largely inhibited by CSPGs and that
inhibition can be overcome by the bacterial enzyme
Chondroitinase ABC. In parallel, we have generated a
stable OEC cell line overexpressing the Nogo receptor
(NgR) ectodomain to reduce MAI-associated inhibition
in vitro and in vivo. Results indicate that engineered cells
migrate longer distances than unmodified OECs over
myelin or oligodendrocyte-myelin glycoprotein (OMgp)-
coated substrates. In addition, they also show improved
migration in lesioned spinal cord. Our results provide new
insights toward the improvement of the mechanisms of
action and optimization of OEC-based cell therapy for
spinal cord lesion.
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Abbreviations
CGN Cerebellar granule neurons
ChABC Chondroitinase ABC
CNS Central nervous system
CSPG Chondroitin sulphate proteoglycan
eGFP Enhanced green fluorescence protein
FTTM Fourier transform traction microscopy
GDNF Glial-derived neurotrophic factor
GFAP Glial fibrillary acidic protein
HRP Horseradish peroxidase
MAIs Myelin-derived molecules
NgR Nogo receptor
OEC Olfactory ensheathing cell
OMgp Oligodendrocyte-myelin glycoprotein
SCI Spinal cord injury
TFM Traction force microscopy
TUJ-1 b3-Tubulin
Introduction
Spontaneous regeneration of damaged axons in the le-
sioned spinal cord is poor, often resulting in a permanent
loss of motor and sensory function [1, 2]. The inhibitory
environment for axonal regrowth generated by the
meningo-glial scar is the main obstacle to regeneration
after lesion [3–5]. Current strategies to enhance functional
regeneration after spinal cord injury (SCI) include gene
therapy, biochemical and/or pharmacological treatment,
and cell transplantation [6–8]. In this scenario, olfactory
ensheathing cells (OECs) have attracted particular attention
as a therapeutic cell transplantation strategy [9, 10]. During
mammalian lifespan, OECs are capable of ensheathing and
guiding newly growing axons of olfactory sensory neurons
from the olfactory mucosa to their targets in the CNS [11,
12]. Indeed, OECs have been successfully used in many
transplantation experiments following SCI, with encour-
aging outcomes (e.g., [13–15]). The precise mechanisms
accounting for the observed recovery are not fully under-
stood but may include promotion of axonal regeneration,
remyelination, neuroprotection, and induction of neovas-
cularization (see [9] for recent review). The migratory
potential of OECs is crucial to their function [16]. How-
ever, studies of the migration capacity and behaviour of
OECs after transplantation in SCI models have led to
contradictory results [17–19]. Nevertheless, it has been
demonstrated that in injured spinal cord, rat and human
OECs migrate for shorter distances, in both rostral and
caudal directions, compared to non-injured spinal cords
[20]. At the molecular level, GDNF [21], Slit-2 [22, 23],
NogoA [24, 25] and fibulin-3 [26] have been demonstrated
to regulate OEC migration. In fact, we and others have
demonstrated that the OEC migratory potential is largely
impaired by myelin [24, 25, 27, 28] and that this inhibition
may be partially overcome by treatment with NEP1-40
peptide [24] or antibodies against the myelin receptor Nogo
receptor [25]. However, following SCI, myelin-associated
inhibitors (MAIs) as well as chondroitin sulphate proteo-
glycans (CSPGs) and secreted semaphorins are
overexpressed at the site of the lesion and they are exposed
to lesioned axons for protracted times [29–31]. However,
although OEC transplantation has been combined with
enzymatic degradation of CSPGs [32–34], whether CSPG
and secreted semaphorins can also inhibit both axon re-
growth and OEC migration is unknown.
In a previous study, we determined the effects of myelin
extracts and CSPG on OEC migration, using video time-
lapse, traction force microscopy and biochemical methods
[24]. In the present study, we analysed the behaviour of
OECs cultured on CSPGs- or Oligodendrocyte-Myelin
Glycoprotein (OMgp)-coated substrates. CSPG-mediated
inhibition of OEC migration can be abolished using
ChABC. In addition, we genetically modified a stable cell
line of OECs (TEG3 cell line [35]) to produce and secrete
the extracellular domain of the Nogo receptor protein
[NgR(Ecto)] to enhance migration in myelin-derived in-
hibitors. In fact, NgR(Ecto) is a truncated form of the
receptor that binds to MAIs, preventing their binding to the
NgR complex by interacting with full-length NgR1 and
blocking the intracellular signalling of MAIs [36, 37].
Moreover, following SCI, intrathecal and intraperitoneal
injections of NgR(Ecto) improved axon regeneration of
transected axonal tracts and functional recovery [38, 39].
Our results demonstrate that NgR(Ecto)-expressing OECs
migrated longer distances in vitro in comparison to non-
modified OECs. In addition, we show that after implanta-
tion in a lesioned spinal cord of adult rats, NgR(Ecto)-
OECs also migrate longer distances than non-modified
cells. Our results provide new insights toward improve-
ment of the mechanisms of action and optimization of
OEC-based cell therapy for SCI.
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Methods
Antibodies and biochemical reagents
The following antibodies were used at a dilution of 1:500
for immunohistochemistry and/or western blotting: S100b
and b3-Tubulin (TUJ-1, 1:4000) purchased from Abcam
(Cambridge, MA, USA), glial fibrilary acidic protein
(GFAP) and green fluorescence protein (GFP) antibodies
from DAKO (Glostrup, Denmark), and p75 from Promega
(Madison, WI, USA). NgR1 was a gift from B.L. Tang
(Singapore). Alexa Fluor 488 goat anti-mouse and Alexa
Fluor 568 goat anti-rabbit immunoglobulins were pur-
chased from Molecular Probes (Leiden, Netherlands). The
goat anti-mouse horseradish peroxidase (HRP) and rabbit
anti-goat-HRP secondary antibodies used in Western blots
were from DAKO. Tubulin (1:5,000), Phalloidin-Alexa
488, and DAPI were from Sigma (St. Louis, MO, USA).
CSPG and OMgp proteins were purchased from R&D
Systems (Minneapolis, MN, USA). Myelin extract was
obtained as [40] and NogoA-containing membranes as [41].
Cloning of the NgR ectodomain [NgR(Ecto)]
and lentiviral production
The NgR(Ecto) construct (Supplementary Fig. S1) was
prepared as follows: the cDNA of the region was cloned by
PCR from adult mouse brain with the primers: NgR(Ecto)
Forward 50- AAA GGA TCC ATG AAG AGG GCC TCC
TCC GGA-30, and NgR(Ecto) Reverse 50-AAT GGA TCC
TTA TCA AGC ACA ACC CTC TAA GTC ACT-30. The
NgR(Ecto) PCR fragment was extracted (QIAquick, QIA-
GEN, Hilden, Germany) and subcloned into the pLenti6/
V5-DEST vector (Invitrogen, Grand Island, NY, USA) into
ApaI and BclI sites. This NgR(Ecto) vector was then se-
quenced to ensure correct nucleotide sequence.
Subsequently, lentiviral particles were produced by tran-
sient transfection of 293FT cells with Lipofectamine 2000
(Invitrogen), using the NgR(Ecto) vector, the second gen-
eration packaging construct psPAX (Tronolab, Lausanne,
Switzerland) and the envelope plasmid pMD2G (Trono-
lab). 293FT cells (Invitrogen) were cultured in DMEM
supplemented with 10 % foetaB calf serum and without
antibiotics before transfection. Medium was changed and
supplemented with antibiotics after 6 h. Medium super-
natants containing viral particles were harvested 24 and
48 h later and concentrated by ultracentrifugation (2 h at
26,0009g at 4 C).
TEG3 cultures and infection strategy
The immortalized clonal cell line TEG3, which contains
the SV40 large T antigen stable transfectant of OEG
primary cultures, was used [35]. Cells were maintained in
ME10: DMEM–F12 (Invitrogen) supplemented with 10 %
bovine calf serum (SAFC Biosciences, Lanexa, VA, USA),
20 lg/ml pituitary extract (Invitrogen), 2 lM forskolin
(Sigma), 1 % penicillin–streptomycin, and 1 % fungizone
(Invitrogen). TEG3 cells were transfected using a lentivirus
carrying the NgR(Ecto) construct and/or one lentivirus
carrying the eGFP construct (Supplementary Fig. S1). Cells
in passage 2 were plated at 2,000 cells/cm2 and incubated
with one of the lentiviruses for 48 h. Then, the medium
was changed and the cells cultured as described above with
the addition of Blasticidin (3 lg/ml, Sigma) to the medium
in the case of the NgR(Ecto). For double transfection, cells
were first incubated with the NgR(Ecto) lentivirus, and
afterwards with the eGFP. Single clones were selected with
cloning disks (Sigma) and expression of NgR(Ecto) was
tested in these clones by western blot. Selected clones were
grown in ME10 media.
Immunocytochemical methods on TEG3 cells
Glass coverslips (12 mm diameter) were coated with pro-
teins essentially as described [36]. Briefly, coverslips were
pre-coated with Poly-L-Lysine 10 lg/ml dissolved in 0.1 M
PBS (pH 7.3) and then washed. They were coated with
laminin (2 lg/ml, dissolved in 0.1 M PBS) and washed
again with 0.1 M PBS. NgR(Ecto)-TEG3 cells were seeded
onto substrate-coated coverslips in ME10 medium. Cells
were cultured for 20 h and then the coverslips were fixed in
4 % buffered paraformaldehyde for 30 min, permeabilized
with 0.1 % Triton X-100, and blocked with 10 % normal
serum in both diluted in 0.1 M PBS. Cells were sequen-
tially incubated overnight with primary antibodies at 4 C
and with Alexa Fluor-tagged secondary antibodies for 1 h.
After rinsing in 0.1 M PBS, cells were stained with 0.1 M
DAPI diluted in 0.1 M PBS for 10 min, rinsed in 0.1 M
PBS, and mounted on FluoromountTM (Vector Labs, Bur-
lingame, CA, USA); they were then analysed using a
fluorescence microscope equipped with a cooled camera
(Olympus BX61 ? DP12L camera).
Nogo66-AP binding assays
Binding experiments were developed essentially as de-
scribed [42]. TEG3 cells (75 % confluence) were fixed in
methanol at -80 C for 5 min. After rehydrating in 0.1 M
PBS, they were overlaid with different concentrations of
Nogo66-AP (kindly provided by Zhigang He) diluted in
Hanks Balanced Salt Solution (HBSS, Invitrogen) and
20 % FCS for 90 min, washed, and fixed in 3.7 %
paraformaldehyde. Endogenous phosphatase was heat in-
activated at 65 C. The AP-fusion protein was viewed
through an enzymatic reaction with a solution containing
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34 M of Nitroblue tetrazolium and 18 M of 5-bromo-
4chloro-3-indolylphosphate (Invitrogen). For competition
experiments, NgR(Ecto) was added at different concen-
trations during Nogo66-AP incubation. AP levels (blue
reaction) were measured using a spectrophotometer (Dynex
Technologies, VA, USA).
In vitro experiments with cerebellar granule neurons
(CGNs)
CGNs from P5-P7 mouse (CD1 strain, Charles River, Ly-
on, France) pups were dissociated by combined
trypsinization as described previously [43]. Cells were
placed in 24-well tissue culture dishes (Nunc, Roskilde,
Denmark) on coated coverslips (see below) and grown for
24–48 h in DMEM medium supplemented with N2 and
B27 (Invitrogen). The procedures were used to treat cells
with MAIs or myelin; the cell surface was coated with
purified myelin essentially as described [40]. After treat-
ments with the TEG3-produced NgR ectodomain, cells
were fixed in 4 % buffered paraformaldehyde and stained
with TUJ-1 antibody and Alexa Fluor 568-tagged sec-
ondary antibody. After rinsing, coverslips were mounted in
FluoromountTM and photodocumented. Neurite length in
cultured CGNs was assessed following image acquisition
using ImageJTM software. A total of 50–57 neurons were
measured in each condition.
Time-lapse analysis of cell migration
Fluorodish cell culture dishes (World Precision Instru-
ments, Sarasota, FL, USA) were coated with laminin or
myelin as above. 5 9 104 cells were seeded in the coated
dishes and 20–24 h later the time-lapse analysis was per-
formed. Culture dishes were transferred to an LCI system
(Live Cell Instruments, Seoul, Korea) for 20 h. Tracking
was performed with an inverted Olympus microscope IX71
(20X Objective) and images (5 megapixels each) were
captured with an Olympus XC50 camera (150 frames, one
frame every 8 min. 20 h in total). Cell tracking allows
analysis of the scrolling speed and frame position (Xt, Yt).
The multi-tracking analysis was performed with ImageJTM
software using the plugin mTrackJ (Biomedical Imaging
Group Rotterdam of the Erasmus MC-University Medical
Center Rotterdam, Netherlands).
In vitro experiment on microfluidic devices
Embryonic cortical neurons were cultured in compart-
mented microchips (Cat. SND900, XonaTM microfluidics,
Temecula, CA, USA) (see [44] for details). Both reservoirs
(axonal and soma) were coated overnight with Poly-D-
Lysine to ensure that the protein also coated the surface of
the 900 lm long bridge channels. The following day the
axonal compartment was also coated with OMgp as above.
To avoid diffusion of the OMgp from the axonal to the soma
compartment, a larger amount ([15 %) of medium was
added to the soma compartment during the experiment.
Cortical neurons were seeded and after an additional 2 days
in vitro, eGFP-TEG3 or eGFP-NgR(Ecto)-TEG3 cells
(2 9 105) were seeded in the axonal compartment. After an
additional 10 days in vitro, microchips were fixed in 4 %
buffered paraformaldehyde and rinsed in 0.1 M PBS. After
rinsing in 0.1 M PBS, chips were incubated with TUJ-1 and
eGFP antibodies for two days at 4 8C and 6 h with the
appropriate Alexa-tagged secondary antibodies. After
rinsing, both soma and axonal compartments were filled
with FluoromountTM in 0.1 M PBS (2:1 diluted) and
photodocumented. The length of the cortical neurons in the
axonal compartment was measured using ImageJTM soft-
ware. A total of 20 chips were analysed in each condition.
Traction force microscopy measurements
Cell tractions were evaluated using constrained Fourier
transform traction microscopy (FTTM) [45]. PAA gels
were coated with laminin, CSPG, or OMgp as described
[24], and cells were cultured over the PAA-coated gels.
Briefly, to obtain a stiff gel of 12 kPa Young Modulus
(PAA), 265 ll of an Acrylamide/Bis-acrylamide mixture
(15 % Acrylamide and 6.5 % Bis-acrylamide, Bio-Rad)
were dissolved in ultrapure water containing 0.4 % of
0.2 m diameter red fluorescent beads (Invitrogen), 0.5 %
ammonia persulfate, and 0.05 % TEMED (Bio-Rad). For
multi-tracking, the mixture was added to the centre of the
dish, which was then coated and stored overnight at 4 C.
The displacement field was calculated by comparing
fluorescent microbead images obtained during the ex-
periment with a reference image taken at the end of the
experiment after the trypsinization and the consequent
detachment of OECs from the underlying substrate. The
projected cell area was calculated with MatlabTM, based on
the manual tracing of the OEC contours determined by a
phase contrast image obtained at the start of the ex-
periment. A particle imaging velocimetry algorithm [46]
was used to determine the deformation of the substrate
caused by the traction forces. The number of analysed cells
in each condition is indicated in the Results section.
Surgical procedures and cell transplantation
Adult female Sprague–Dawley rats (9 weeks old;
250–300 g weight) were used in the spinal cord ex-
periments. The animals were housed with free access to
food and water at room temperature of 22 ± 2 C under a
12:12 h light–dark cycle. The experimental procedures
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were approved by the ethical committee of the Universitat
Autonoma de Barcelona and the IBEC in accordance with
European Directive 86/609/EEC. Under anaesthesia with
ketamine (90 mg/kg) and xylacine (10 mg/kg) and aseptic
conditions, laminectomy was performed in T8–T9 vertebra
and a cord contusion of 200 Kdyns was induced using an
Infinite Horizon Impactor (Precision System and Instru-
mentation, Kentucky, USA). The cells for transplantation
(eGFP-TEG3 or eGFP-NgR(Ecto)-TEG3) were suspended
in L15 medium (Invitrogen) at 50,000 cells/ll and main-
tained in ice during the time of surgery. 30 min after the
lesion, using a glass needle (100 lm internal diameter,
Eppendorf, Hamburg, Germany) coupled to a 10 ll
Hamilton syringe (Hamilton #701, Hamilton Co, NV,
USA), 6 ll of the corresponding cell suspension was in-
traspinally injected (1 mm deep into the spinal cord, 2
injections of 3 ll each, one at each side 1 mm lateral to the
lesion point), with a total of 150,000 cells per injection
(300,000 cells/rat). A perfusion speed of 2 ll/min was
controlled by an automatic injector (KDS 310 Plus, Kd
Scientific, Holliston, MA, USA), and the needle tip was
maintained inside the tissue 3 min after injection to avoid
liquid reflux. A total of six rats were used (3 rats received
eGFP-TEG3 cells, and the other 3 eGFP-NgR(Ecto)-TEG3
cells). The wound was sutured by planes and the animals
allowed to recover in a warm environment. Bladders were
expressed twice a day. To prevent infection, amoxicillin
(500 mg/l) was given in the drinking water for one week.
Tissue processing
Seven days post-implantation, rats were deeply anaes-
thetized (pentobarbital 60 mg/kg b.w. i.p.) and
intracardially perfused with 4 % paraformaldehyde in
0.1 M PBS. The spinal cord segment from 1.5 cm rostral to
1.5 cm caudal to the injection (±3 cm total length) was
harvested and post-fixed in the same fixative solution for
24 h and cryopreserved in 30 % sucrose. For GFP-positive
cell localization, 30 lm thick longitudinal cryostat sections
of the spinal cord segment were obtained. Spinal cord
sections of cell-transplanted rats were processed for im-
munohistochemistry against GFP and GFAP. Tissue
sections were incubated with 0.1 M PBS Triton X-100,
5 % foetal bovine serum during 4 h and 24 h at room
temperature with with primary antibodies at 4 C. After
washing, sections were incubated for 2 h at room tem-
perature with the secondary antibody. Slides were
dehydrated and mounted with Citoseal 60 (Thermo Fisher
Scientific, Madrid, Spain). For analysis, images (10
megapixels) were obtained with a digital camera (Leica
DFC 550) attached to the microscope (Leica AF700).
Starting from the injection points, 11 consecutive sections
of the length of approximately 200 lm were captured.
GFP-positive cells in each section were counted.
Statistical analysis
Summary data are expressed as mean ± S.E.M (standard
error of the mean) of at least three independent experiments
(unless indicated). Data were analysed using Bonferroni
post hoc test (Multiple comparison test) using Prism 5
(Mac OsX, Grahpad). A value of **P\ 0.05 was consid-
ered statistically significant.
Results
Reduced migration and traction forces in cultured TEG
cells mediated by CSPGs and OMgp
TEG3 is a clone OEC line that shows similar growth
promoting potential to non-modified OECs (e.g., [35]. In
addition, previously published data reported that TEG3 cell
migration is inhibited by myelin [24] as happens with non-
modified OECs [25]. Because of the lamellipodial activity
of the OECs that seems to play a crucial role in OEC
migration [47] and regeneration properties [48], we anal-
ysed the membrane dynamics in OECs over different
substrates (Fig. 1). TEG3 cells growing on laminin-coated
substrates showed a bipolar morphology with numerous
dynamic filopodia and lamellipodia (Supplementary Movie
1). The migration of these cells is similar to those observed
in cultured fibroblasts (e.g., NIH/3T3 fibroblasts; ATCC
CRL-1568) with random trajectories (see below). LifeAct-
eGFP transfected TEG3 cells showed an intense remod-
elling of the Actin cytoskeleton during migration
(Supplementary Movie 2 and Fig. 1a). Thus, video time-
lapse experiments used to analyse the dynamics of the cell
membrane showed increased dynamics of TEG3 growing
over laminin (Fig. 1a, d) compared with TEG3 cells
growing on CSPG (Fig. 1b, e) or OMgp-coated (Fig. 1c, f)
substrates. This also correlates with decreased cell protru-
sions observed in GFP immunoreacted cells (Fig. 1a–c)
and in scanning electron microscopy (SEM) observations
(Fig. 1g–i).
Next, TEG3 migration over laminin, CSPG-, and
OMgp-coated substrates was monitored for 20 h in video
time-lapse experiments (20X objective; one frame every
8 min)(Fig. 2 and Supplementary Movies 3–5). A three-
axis plot (x/y position vs time (hours)) revealed higher
motile persistence on laminin coated (Fig. 2d) than on
CSPG- (Fig. 2e) or OMgp-coated (Fig. 2f) substrates.
Quantitatively, the migration speed of TEG3 s cells over
laminin was 0.81 ± 0.03 lm/min. In contrast, TEG3 cells
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growing over CSPG- or OMgp-coated substrates showed a
dramatic decrease in the migrated speed ranging from 63 to
76 % (0.27 ± 0.05 lm/min (OMgp, 10 lg/ml) to
0.19 ± 0.02 lm/min (CSPG; 25 lg/ml).
Mounting evidence demonstrates that cells generate
traction forces against their substrate during adhesion and
migration, and traction forces are used by cells to sense the
extracellular matrix in healthy and unhealthy conditions
(e.g., [49, 50]). Thus, using traction force microscopy
(TFM), we aimed to determine the distribution of traction
forces in TEG cells cultured on a well-characterized poly-
acrylamide (PAA) gel, which is linearly elastic, optically
clear, and suitable for protein conjugation ([51] see for de-
tails). Using TFM, we observed that cells seeded on laminin-
coated substrates transferred higher strain energy
(0.01389 ± 0.004, PJ; n = 16) (Fig. 2h) to their underlying
substrate than those seeded on CSPG- (0.00018 ± 0.0001,
PJ; n = 35) (Fig. 2i) or OMgp-coated substrate
(0.00032 ± 0.0001, PJ; n = 29) (Fig. 2j) (laminin vs CSPG
t = 6.362 and laminin vs OMgp t = 6.086; P\ 0.05).
Fig. 1 Morphological changes triggered by CSPG and OMgp in
cultured TEG3 cells. a–i LifeAct-eGFP (a–c), QuimP analysis (d–f),
and SEM (g–i) microscopy photographs of TEG3 cells growing on
laminin- (a, d, g), CSPG- (b–h), and OMgp- (c, f, i) coated substrates.
Note the large decrease in F-Actin containing lamellipodia and
membrane dynamics in the presence of CSPG and OMgp. In the
QuimP analysis (d–f), the limit of the plasma membrane is delineated
by different colour lines [by time = 0 (green) to 60 min (yellow)].
Note that yellow lines are in between green lines, in CSPG (h) and
OMgp (i), in contrast to laminin (b), which suggests that cells are
unable to generate protrusive forces. Scale bars a and g = 20 lm;
pertain to b, c and h–i, respectively. d = 5 lm pertains to e–f
cFig. 2 Migratory behaviour and traction force strain of TEG3 cells in
laminin-, CSPG- and OMgp-coated glass substrates. Examples of
TEG3 cell migration on laminin- (a), CSPG- (b), and OMgp-
(c) coated glass substrates. Each cell trajectory is labelled with a
different colour line after the software analysis (ImageJTM). (d–
f) Examples of three-axis representation of the trajectories of
identified TEG3 cells in the focal plane (x, y) along time (z axis, h)
on laminin (d), CSPG (e) and OMgp (f). Note that identified TEG3
cells do not modify their (x, y) position over time (e and f) with few of
them showing small displacements (arrowhead) compared to laminin
(d). g Histograms showing the speed (Y axis) of cultured TEG3 cells
on laminin (black bars), and two concentrations of CSPG (grey bars)
and OMgp (open bars). h–j Quantitation of cellular traction forces of
cultured TEG3 cells in PAA-laminin (h), PAA-CSPG (i) and PAA-
OMgp (j). A phase contrast image of examples of cultured cells is
shown on the left side. The scale in lm is also displayed on the lower
left side of each image. In addition, the force map of cultured cells is
shown in the right column. Arrows indicate the direction of the bead
displacement. The colour scale indicates the magnitude of the cellular
traction force measured in Pa. Data in (g) are represented as
mean ± S.E.M. Asterisks in (g) indicate statistical differences
(**P\ 0.05, one-way ANOVA Bonferroni post hoc test: laminin
vs CSPG (12 lg/ml) t = 15.03; laminin vs CSPG (25 lg/ml)
t = 17.01; laminin vs OmGP (5 lg/ml) t = 14.90; and laminin vs
OmGP (10 lg/ml) t = 15.10)
2724 D. Reginensi et al.
123
Increased migration of olfactory ensheathing cells 2725
123
Fig. 3 Overcoming CSPG inhibition of TEG3 migration by ChABC.
(a–b) Examples of the ChABC effects of individual TEG3 migration
on laminin- (a) and CSPG- (b) coated glass substrates. The trajectory
of selected TEG3 cells without ChABC treatment is labelled in red in
(a) and (b). Yellow lines show the changes observed after incubation
with ChABC in the selected cells. c Histogram showing the results of
the time-lapse analysis and the effect of the ChABC incubation. d–
i Fluorescein photomicrographs illustrating examples of TGE cells
growing on laminin (d, g), CSPG (e, h) and CSPG ? ChABC (f, i).
Cells were immunoreacted to F-Actin (d–f) and vinculin (g–
i) antibodies and counterstained with DAPI. Arrows in (d) and
(f) point to stress fibres and in (g) and (i) to vinculin-positive focal
contacts. j Quantitation of cellular traction force of cultured TEG3
cells in PAA-CSPG ? ChABC. A phase contrast image of TEG3
cultured cells is shown. The scale and the force map are also shown.
Arrows indicate the direction of the bead displacement and the colour
scale indicates the magnitude of the cellular traction force measured
in Pa as in Fig. 2. k Histogram illustrating the quantitative results of
the TFM analysis. Data in (c) are represented by mean ± S.E.M.
Scale bars a = 200 lm pertains to b. c and g = 200 lm pertains to e,
f and g, i respectively. Asterisks in (c) (laminin vs CSPG (-ChABC)
t = 17.53; laminin vs CSPG (? ChABC) t = 10.03; CSPG vs CSPG
(? ChABC) t = 7.759) and (k) (laminin vs CSPG (-ChABC)
t = 6.374; laminin vs CSPG (? ChABC) t = 5.590; CSPG vs CSPG
(? ChABC) t = 5.03) indicate statistical differences (**P\ 0.05
one–way ANOVA Bonferroni post hoc test)
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Effects of ChABC treatment on TEG3 cell migration
and traction forces over CSPG-containing substrates
The bacterial enzyme ChABC liberates chondroitin
suphate GAGs from CSPG core proteins to render a more
permissive substrate for axonal outgrowth [34, 52].
ChABC acts on chondroitin 4-suphate, chondroitin 6-sul-
phate, and dermatan sulfated proteogycans, and acts very
slowly on hyaluronate. This enzyme has been used to
promote axon regeneration in lesioned spinal cord in single
and combined treatments (e.g., [34, 53–55]). In fact,
ChABC has been used in combination with OECs [32, 56],
and the expression of ChABC has also been directed to
Schwann cells [57] and astrocytes [58] with relevant re-
sults. In our study, TEG migration and traction forces were
decreased by CSPGs (see above). Thus, we aimed to de-
termine whether ChABC treatment affected intrinsic OEC
migratory properties and whether it was able to rescue their
migration when cultured over CSPGs (Fig. 3). Control
experiments demonstrated that ChABC treatment did not
modify the migration or the traction forces of cultured
TEGs over laminin (Fig. 3a, c and Supplementary Movie
6), myelin, or OMgp (not shown). TEG3 migration over
CSPG-coated substrates was 0.19 ± 0.05 lm/min (CSPG;
25 lg/ml). A = 60 % increase in the migratory speed was
observed after treatment with ChABC (0.48 ± 0.07 lm/
min) (Fig. 3b, c and Supplementary Movie 7). F-actin and
Vinculin staining on TEG3 cells growing on CSPG-coated
substrates demonstrated increased lamellipodia and the
presence of Vinculin-positive aggregates after ChABC
treatment (Fig. 3d–i). In parallel, these increased Vinculin
aggregates correlated with increased traction force as de-
termined with TFM (0.00179 ± 0.0004, PJ; n = 35)
(Fig. 3j–k).
Fig. 4 Generation of the TEG3 cell lines overexpressing NgR(Ecto).
a Western blot illustrating the expression of the NgR(Ecto) in TEG3
cells after lentiviral delivery of eGFP (? or -) and NgR(Ecto)
(? or -). Arrows point to the proteins of interest. Tubulin was
immunoblotted as control protein. b Western blotting illustrating the
presence of NgR(Ecto) in the culture media of TEG3 cells after the
lentiviral delivery of eGFP and NgR(Ecto) as above. c–e Example of
the expression of eGFP (e) and NgR1 (i) in double-infected cells. f–
i Fluorescence photomicrographs of eGFP-NgR(Ecto)-TEG3 cells
immunoreacted to p75 (f), S100b (g), F-Actin (h), and vinculin
(i) detection. Scale bars c and f = 200 lm pertains to d, e and
g respectively. h = 50 lm pertains to I
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Generation and characterization of NgR(Ecto)-TEG3
cells
TEG3 cell lines producing and secreting the extracellular
domain (1–310 aa) of the NgR1 receptor were generated by
lentiviral infection and selected with Blasticidin (see
Methods for details). In addition, selected clones were in-
fected with eGFP-expressing lentivirus (Fig. 4). Clones
([95 % eGFP-NgR(Ecto)-TEG3) were selected by the
expression levels of the ectodomain. With western blotting,
we detected the ectodomain in both cell extracts and in
cultures (Fig. 4a and Supplementary Fig. S2). eGFP co-
expression in NgR(Ecto) producing cells did not modify
the expression of ectodomain (Fig. 4a–c). In addition,
eGFP-positive NgR(Ecto)-TEG3 cells maintained p75 or
S100b expression (Fig. 4d, e) and displayed the range of
Fig. 5 The NgR(Ecto) generated by engineered TEG3 cells is
functional. a–e Binding experiments of NgR(Ecto) in TEG3 cells.
TEG3 cells were incubated with mock media (obtained from cells
transfected with empty vector; SEAP) (a), 300 nM Nogo66-AP
(b) and 300 nM Nogo66AP ? 300 nM NgR(Ecto) (c). Note the
decrease in the AP labelling in (c) compared to (b). Increasing levels
of O.D. at different Nogo66-AP can be seen in (d). Histogram
illustrating the quantitative results of the experiment is presented in
(c). f–i NgR(Ecto) induce large neurite extension of cultured CGN
over Poly-L-Lys (f) or NogoA (g–h) containing membranes, in the
presence (i) or absence (h) of 150 nM NgR(Ecto). Arrows in (f–h)
point to the end of the measured CGNs neurites. Data in (e) and (i) are
represented by mean ± S.E.M. Scale bars a = 1000 lm pertain to b
and c. f = 30 lm pertains to g and h. Asterisks in (e) and (i) indicate
statistical differences (e.g., Membrane ? mock vs NogoA mem-
brane ? mock t = 18.99; NogoA membrane ? mock vs NogoA
membrane ? NgR(Ecto) t = 17.08; ***P\ 0.05, one-way ANOVA
Bonferroni post hoc test)
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morphologies (astrocyte- or Schwann cell-like) described
for cultured primary OEC and TEG3 cells (Fig. 4f–i)(e.g.,
see also [24, 27], for details).
TEG3-generated NgR(Ecto) blocks Nogo66-AP
binding to Nogo receptor
As indicated above, OECs and TEG3s express all members
of the Nogo receptor complex (e.g., [24, 25, 59]). Thus, to
determine whether the NgR(Ecto) produced by TEG3 cells
was active, we incubated TEG3 cells (&75 % confluence)
with Nogo66-AP in the absence or presence of NgR(Ecto)-
containing solution (Fig. 5a–e). After incubation, AP ac-
tivity in treated cells was measured at 405 nm
spectrophotometer (Fig. 5d, e). Results revealed a decrease
of&18 and&55 % in the OD values after incubation with
150 nM or 300 nM TEG-produced NgR(Ecto) (Fig. 5e). In
addition, we incubated with TEG3-generated NgR(Ecto)
CGNs cultured on Poly-D-Lysine (Fig. 5f, g), as well as
cell membranes of Mock- and NogoA-transfected HEK293
cells (Fig. 5f, g). Cultured CGNs were labelled using the
TUJ-1 antibody. Neurite length of CGNs cultured over
NogoA membranes was reduced to &40 % compared to
Mock-transfected and Poly-D-Lysine values (Fig. 5g)
(Poly-D-Lys ? Mock = 100.5 ± 10.94; vs Membrane ?
Mock = 103 ± 13.82 vs NogoA Membrane ? Mock =
61.30 ± 9.82). This value reached a & 30 % increase
when cultured with [150 mM] NgR(Ecto) (Fig. 5g) (No-
goA Membrane ? Ngr(Ecto) = 85.43 ± 13.01). The
addition of NgR(Ecto) did not modify CGN neurite length
Fig. 6 Increased axonal growth of cortical neurons induced by eGFP-
NgR(Ecto)-TEG3 cells in microfluidic compartmentalized devices. a,
b Photomicrographs illustrating examples of E15.5 cortical neurons
cultured on XonaTM microfluidic devices coated with Poly-D-Lys
(a) or OMgp (b) for 12 days (see Methods for details). c, d Examples
of the combined co-culture of E15.5 cortical neurons and eGFP-TEG3
cells (c) or eGFP-NgR(Ecto)-TEG3 cells (d). After fixation, mi-
crofluidic devices were processed for TUJ-1 and eGFP
immunostaining. e, f High power photomicrographs of double-
labelled microfluidic devices containing cortical axons (red) and
eGFP-NgR(Ecto)-TEG3 (green). Note that eGFP-NgR(Ecto)-TEG3
cells do not seem to be in contact with growing axons (arrows). g
Histogram illustrating the quantitative results of the experiment
illustrated in (a–d). The ends of the bridge channels are labelled by a
white dashed line in (a–d). Data in (g) are represented as mean ± -
S.E.M. Scale bars a = 100 lm pertain to b–d. Asterisks in
(g) indicate statistical differences (laminin vs OMgp t = 17.8;
laminin vs OMgp ? eGFP-TEG3 t = 16.43; OMgp ? eGFP-TEG3
vs OMgp ? eGFP- NgR(Ecto)-TEG3 t = 6.87; **P\ 0.05; one-way
ANOVA Bonferroni post hoc test)
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when cultured over control HEK293 membranes (Mem-
brane ? NgR(Ecto) 97.5 ± 11.52 vs Membrane ?
Mock = 103 ± 13.82).
NgR(Ecto)-TEG3 cells overcome OMgp inhibition
to cortical axons in microfluidic platforms
Compartmentalized neuronal cultures of lab-on-a-chip de-
vices have been used for different studies in recent years
(see [60] for a recent review). Due to this specific design,
media located in the axonal reservoir are unable to diffuse
to the soma reservoir [61]. Thus, we aimed to determine
whether NgR(Ecto)-TEG3 cells are able to stimulate axon
outgrowth over inhibitory MAI-containing substrates
(Fig. 6). Indeed, E15.5 cortical neurons cultured in one
reservoir of the microfluidic platforms are able to cross the
900 lm long bridge channels in one week to reach the
recipient or axonal reservoir (Fig. 6a). In these conditions,
cortical axons were able to spread in laminin-coated axonal
reservoirs (Fig. 6a) expressing NgR receptor 3. Their ax-
onal length was reduced by &25 % when OMgp was
present as substrate in the axonal reservoir (Fig. 6b). Next,
we co-cultured eGFP-TEG3 and eGFP-Ngr(Ecto)-TEG3
cells in the axonal reservoir of parallel chips with E15.5
cortical neurons and coated with OMgp, as above (Fig. 6c,
d, e–g). Results indicated that eGFP-TEG3 was unable to
statistically increase neurite length of cultured cortical
neurons in the devices (Fig. 6c, g). In contrast, eGFP-
NgR(Ecto)-TEG3 cells were able to increase by &24 %
the axonal length of the cultured cortical neurons on OMgp
(Fig. 6d, e–g) (up to 95 % of the value obtained in the
presence of laminin, Fig. 5g). However, we were unable to
observe a clear interaction between cortical axons and
eGFP-NgR(Ecto)-TEG3 cells in our microfluidic devices,
suggesting that these positive effects were mediated by the
secreted NgR(Ecto) in the axonal compartment (Fig. 6e, f).
Increased migration of NgR(Ecto)-TEG3
and NgR(Ecto)-treated TEG3 cells on MAI-coated
substrates
Next we aimed to explore the migratory properties of
NgR(Ecto)-TEG3 cells compared to TEG3 cells over in-
hibitory substrates and the specific effect of NgR(Ecto) on
TEG3 cell migration over OMgp (Fig. 7). Indeed, TEG3
migration over laminin, myelin- and OMgp-coated sub-
strates was monitored for 20 h in video time-lapse
experiments as above. Quantitatively, in these experiments
the migration speed of TEG3s cells over laminin was
0.79 ± 0.05 lm/min (n = 38) (Fig. 7c) and
0.82 ± 0.04 lm/min (n = 36) (Fig. 7f). In contrast, TEG3
cells growing over myelin- or OMgp-coated substrates
showed a decrease in migrating speed (0.3 ± 0.04 lm/min
(Myelin; n = 35) (0.24 ± 0.02 lm/min (OMgp, 10 lg/ml;
n = 35) as expected. NgR(Ecto)-TEG3 cells migrated as
TEG3 cells over laminin (0.79 ± 0.05 lm/min; n = 38)
(Fig. 7c) but with increased speed over myelin
(0.55 ± 0.04 lm/min; n = 37) (Fig. 7c and Supplementary
Movie 8) and OMgp (0.47 ± 0.02 lm/min; n = 36)
(Fig. 7f and Supplementary Movie 9). In addition, when
NgR(Ecto) was added to migrating TEG cells growing on
OMgp-coated substrates, a 1.81-fold increase of the migra-
tory speed was observed [0.49 ± 0.03 lm/min; n = 48
(TEG3 ? NgR(Ecto)] and 0.27 ± 0.02 lm/min; n = 37)
[TEG without NgR(Ecto)] (Fig. 7g–l and Supplementary
Movies 10, 11). In addition, both TEG3 cells treated with
NgR(Ecto) (Fig. 7k, n) and NgR(Ecto)-TEG3 cells (Fig. 7l,
o) growing over OMgp displayed relevant filopodia (Fig. 7k,
l) with abundant puncta-like staining of vinculin, suggesting
increased focal contacts (Fig. 7n, o) compared to parallel
TEG cell cultures (Fig. 7j, m). In parallel, these data cor-
related with increased traction force on OMgp-coated
treated with NgR(Ecto)-TEG3 (0.00274 ± 0.0006, PJ;
n = 25) and NgR(Ecto) (0.00301 ± 0.0005, PJ; n = 28)
(Fig. 8).
Increased migration of NgR(Ecto)-TEG3 cells
in lesioned spinal cord
To further determine whether NgR(Ecto)-TEG3 cells also
increased their migratory potential in vivo, 300,000 cells of
eGFP- or NgR(Ecto)-TEG3 were implanted in injured
cFig. 7 Enhanced NgR(Ecto)-TEG3 migration over myelin and
OMgp. a–b Examples of TEGs cells (a, d) and NgR(Ecto)-TEG3
(b, e) migration on myelin- (a, b) and OMgp- (d, e) coated glass
substrates. The trajectory of selected cells is labelled by different
colours. The quantification of the above illustrated experiments is
plotted in (c) and (f). (g, h) Examples of the exogenous incubation
with the effects of NgR(Ecto) on individual TEG3 migration on
OMGp-coated glass substrates. The trajectory of selected TEG3 cells
without NgR(Ecto) treatment is labelled in red in (g) and (h). Yellow
lines show the changes observed after incubation with mock media
(g) and NgR(Ecto) (h) in the selected cells. (i) Histogram showing the
results of the time-lapse analysis and the effect of the NgR(Ecto)
incubation on TEG3 cells. f–i Fluorescence photomicrographs of
TEG3 (j,m), NgR(Ecto)-TEG3 cells (k, n), and TEG3 cells incubated
with exogenous NgR(Ecto) (l, o) immunoreacted to F-Actin (j–l) and
vinculin (m–o) detection. All cells were growing over OMgp-coated
substrates. Arrows in (k, l) and (n, o) point to stress fibres and
vinculin-positive focal contacts, respectively. Scale bars: a and
g = 200 lm pertain to b–e and h, respectively. j and m = 50 lm
pertains to (k, l) and (n, o), respectively. Data (in c, f, and i) are
represented by mean ± s.e.m. Asterisks in (c, f and i) indicate
statistical differences (**P\ 0.05, one-way ANOVA Bonferroni post
hoc test). Results in c: laminin vs myelin (TEG3) t = 10.20; laminin
vs myelin (NgR(Ecto)-TEG3) t = 5.11; myelin (TEG3) vs myelin
(NgR(Ecto)-TEG3) t = 5.02. Results in f: laminin vs OMgp ? (-
TEG3) t = 13.56; laminin vs OMgp ? (NgR(Ecto)-TEG3) t = 8.35;
OMgp ? (TEG3) vs OMgp ? (NgR(Ecto)-TEG3) t = 5.21). Results
in i: OMgp ? (Pre-NgR(Ecto) vs OMgp ? (NgR(Ecto)) t = 7.58
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spinal cords to analyse the capacity of these cells to inte-
grate and migrate in the lesion model (Fig. 9). A total of 6
rats were used (3 rats received eGFP-TEG3 cells, and the
other 3 eGFP/NgR(Ecto)-TEG3). A week after transplan-
tation, spinal cords were perfusion fixed and the
localization and distribution of eGFP-positive cells were
analysed (see Method for details). Eight representative
slices were selected for analysis for each animal. The total
number of eGFP-positive cells in the case of eGFP-TEG3s
(6000 ± 250 cells/slice) was slightly less than that of
eGFP-NgR(Ecto)-TEG3s (7000 ± 200 cells/slice). To
assess the distance migrated, we counted the number of
eGFP-positive cells in transversal stripe of about 200 lm in
length starting from the injection point. Eleven lines or
stripe caudal or rostral to the injection points were analysed
(Fig. 8a, c, e). Results revealed that most eGFP-TEG3 s
were distributed near the injection point with the maximum
cell percentage (&25 %) found in the section 400 lm
rostral or caudal to these points (Fig. 9b, c, h). Moreover,
very few eGFP-TEG3 cells were observed more than
1,600–1,800 lm from the injection point (&8–9 stripe;
Fig. 9h). By contrast, eGFP-NgR(Ecto)-TEG3 cells were
found in all 11 stripes analysed (Fig. 9d, e, h) with a pla-
teau in the number of cells (around 13–16 %) found in the
first four sections (&800 lm) rostral or caudal to the in-
jection points decreasing slowly in the following stripes
(Fig. 9h). In addition, increased numbers of eGFP-
NgR(Ecto)-TEG3 cells were also observed on the lesion
side (Fig. 9f, g).
Discussion
In physiological conditions, the migration of most cells
occurs in an adhesion-dependent manner and involves the
formation of FA at the membrane and the generation of
mechanical forces via the actin–myosin network [62].
Traction force comes into play in the synchronization of
these processes in different cell types (e.g., keratinocytes
[62], invasive tumor cells [63], fibroblasts [64, 65]) and
olfactory ensheathing cells ([24] and present results). Thus,
the balance between traction force and adhesion strength
can be understood as a direct indicator of cell migration
capacity. Using TFM and single cell tracking, we showed
the behaviour of TEG3 cells in a quantitative basis
demonstrating that the increased traction force is sufficient
to tilt the mechanical balance toward a pro-migratory
phenotype of OECs [24].
CSPGs as well as MAIs and their receptors modulate the
establishment of this actin–myosin network as well as
microtubule dynamics [5, 66]. Indeed, MAI-induced arrest
of CNS axon growth is either induced after MAI receptor,
the Ca2?-dependent activation of the epidermal growth
factor receptor (EGFr), or induced by sequential RhoA/
RhoK/LIM-kinase/cofilin phosphorylation, leading to actin
depolymerization [67]. In parallel, microtubule stabiliza-
tion is also compromised after exposure to MAIs [68]. Our
results reinforce the notion that molecules present in
myelin extracts act on Nogo receptor complex as well as on
Fig. 8 Increased strain forces of NgR(Ecto)-TEG3 cells and TEG3
cells incubated with exogenous NgR(Ecto) in PAA gels coated with
OMgp. a, b Quantitation of cellular traction forces of cultured
NgR(Ecto)-TEG3 cells (a) and TEG3 cells ? exogenous NgR(Ecto)
(b) growing on PAA-OMgp gels. A phase contrast image of cultured
cells is shown. The scale and the force map are also shown. Arrows
indicate the direction of the bead displacement and the colour scale
indicates the magnitude of the cellular traction force measured in Pa
as in Fig. 2. (c) Histogram illustrating the quantitative results of the
TFM analysis. Data in (c) are represented as mean ± S.E.M.
Asterisks in (c) indicate statistical differences (**P\ 0.05, Bonfer-
roni post hoc test); laminin ? (TEG3) vs OMgp ? (TEG3)
t = 6.304; laminin vs OMgp (NgR(Ecto)-TEG3) t = 4.93; laminin
vs OMgp ? [TEG3 ? NgR(Ecto)] t = 5.15. OMgp ? (TEG3) vs
OMGp ? (NgR(Ecto)-TEG3) t = 5.02; OMgp ? (TEG3) vs
OMGp ? (NgR(Ecto)-TEG3) t = 5.02
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Fig. 9 Enhanced migration of eGFP-NgR(Ecto) into contused spinal
cord. a Scheme of the experimental procedure. b–e Examples of
longitudinal sections of the lesioned spinal cord transplanted with
eGFP-TEG3 (b, c) or eGFP-NgR(Ecto). TEG3 (d, e) cells immunore-
acted to GFAP and eGFP. The boxed areas in (b) and (d) are shown
in (c) and (e), respectively. The 11 columns are indicated in each case.
(f, g) Medium power photomicrographs illustrating eGFP-TEG3
(f) and eGFP-NgR(Ecto)-TEG3 (g) cells at the contused lesion site. h
Histogram illustrating the quantitative results of the experiment
illustrated in (b–e). Data in (h) are represented as mean ± S.E.M. of
the percentage of eGFP labelled cells in each column. Scale bars b–
e = 100 lm
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other receptors, and may modulate OEC cytoskeleton and
FA distribution.
OEC transplantation has been shown to promote re-
generation and functional recovery in lesioned spinal cord
[9, 10]. In that the regenerative properties of OECs are
largely associated with their migration and lamellipodial
dynamics (e.g., [23, 69]) there is a considerable interest in
enhancing OEC migratory capacity. In fact, it is assumed
that OECs migrate ahead of growing axons and by se-
creting supporting factors (e.g., GDNF) [16, 28], or with
matrix metalloproteinase activity [70] aiding and promot-
ing their elongation. These positive effects on axon
elongation have also been described for DRG cells cultured
on myelin in the presence of OECs (e.g., secreting BDNF)
[28]. In a previous study, we demonstrated that OECs ex-
press the NgR receptor complex (NgR1, P75, Lingo1 and
TROY) and that their migration is also impaired by myelin
[24]. In addition, NogoA, Slit2, and fibulin-3 have been
reported as inhibitors of OEC migration. However, the
effects of CSPG on OEC migration have not been previ-
ously studied. Here, we described how CSPGs largely
impair OEC migration by reducing the mechanical strain
force that cells transmit to the coated substrate. This re-
duced force correlates well with the low number of
vinculine-positive focal contacts and profound reorgani-
zation of F-Actin cortical cytoskeleton. In fact, a recent
study described how CSPGs are also ligands for NgR1 and
NgR3 MAI receptors [71]. TEG3 and NgR(Ecto)-TEG3
cells express NgR1 ([24] and present results), which may
explain some of the observed results that point to a func-
tional redundancy between myelin inhibitors and CSPGs
blocking OEC migration. However, because the binding
region of CSPG to NgR1 is located in the Stalk region of
the receptor, no relevant changes were observed between
NgR(Ecto)-TEG3 and TEG3 cell migration over
CSPG)(not shown).
Present results also reinforce the notion that most of
the factors inhibiting axon elongation and regrowth after
lesion may also affect OEC migration. In fact, to date all
the described molecules inhibiting OEC migration—No-
goA, fibulin-3, and Slit2—have been reported to be
overexpressed in CNS scars after lesion [31, 72, 73].
Thus, in this scenario it is reasonable to consider that the
combined treatment developed by Fouad et al, with
ChABC, Schwann cell bridges, and OEC transplantation,
may positively affect both OEC migration and axon re-
growth [32]. Furthermore, secreted semaphorins (e.g.,
Sema3A) are expressed by OECs [74] and seem not to
affect migration of OECs (J.A.D.R. unpublished results).
In this respect, the single genetic ablation of MAIs [75]
alone or with semaphorin receptors [76] is not strong
enough to support axon regrowth after SCI. In contrast,
it seems that blocking the MAI receptors NgR1 and
NgR3 and CSPG receptors yields better results [71]. In
light of the foregoing, we consider that a transplantation
strategy with cells with endogenous neurotrophic support
(producing GDNF or BDNF) and enhanced migratory
properties in parallel with pharmacological treatment
should be strongly considered as a potential combined
therapy for SCI lesion. Indeed, in the present study we
genetically modified TEG3 to express a soluble form of
NgR1 receptor to overcome myelin-derived inhibition
[36]. Results demonstrate that NgR(Ecto)-TEG3 cells
migrate faster in vitro over OMgp and myelin-coated
substrates in vivo as well after contusive lesions of the
spinal cord. In addition, the recovery of migration ca-
pacity correlates with increased traction force observed
in TFM experiments in NgR(Ecto)-TEG3s cells. How-
ever, the two recoveries (migration and strain forces) are
not complete, suggesting that other factors are involved
in this inhibition. Indeed, OECs might respond to other
myelin-associated molecules (e.g., lipids [77]) or express
receptors other than NgR1 (e.g., LDL, receptor related
protein 1) [78], which could exert inhibitory action on
axonal growth. However, whether these lipids could act
on OECs is unknown and warrants further study. Yet
another challenging question remains unsolved since
NgR(Ecto)-TEG3 presents random migration as described
for normal TEG3, which suggests that other strategies
may be needed to generate a persistent and directed
migration in the lesioned spinal cord using directed
chemoattraction [24, 79] on specific functionalized bio-
materials [80, 81]. In conclusion, we have demonstrated
that OEC migration is impaired by CSPG and that an
engineered OEC cell line to produce NgR ectodomain
abolished the inhibitory properties of myelin extract and
purified OMgp. These effects also correlate with in-
creased migration after in vivo transplantation in
contused spinal cord. Future experiments will be directed
to overcoming CSPG inhibition in engineered cells to
enhanced functional axon regeneration after lesion.
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